天沃科技(002564.SZ):預計上半年淨利1250萬元-1650萬元 同比扭虧為盈
格隆匯7月14日丨天沃科技(002564.SZ)披露2021年半年度業績預吿,預計上半年歸屬於上市公司股東的淨利潤1250萬元–1650萬元,同比扭虧為盈。基本每股收益0.01元/股–0.02元/股。
淨利潤增加的主要原因:
1、2020年上半年受新冠疫情影響,公司工程業務開展受阻,收入與毛利較低。報吿期國內疫情得到有效控制,公司相關業務趨於正常,營業收入較去年同期增長,毛利與收入同比增長。
2、報吿期內,公司完成將全資子公司天沃恩科(北京)核物理研究院有限公司100%股權出售給太平洋機電(集團)有限公司的交易,交易總價為2.15億元,產生非經常性損益約5000萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.